drugset
drugset / Trial / NCT00058253

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00058253 ↗

Phase 1 Completed 80 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as docetaxel and 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Timeline

Start
2003-02
Primary completion
2008-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown — Intravenous
Background Docetaxel Small molecule — Intravenous

Indications

prostate carcinoma